A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.
And four other potential targets that could make sense for the beleaguered group.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.